期刊簡介 | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Analytical Cellular Pathology LetPub Score 4.9
50 ratings
Rate
Reputation 5.9 Influence 3.6 Speed 7.0 | ||||||||||||||||||||||||||||
期刊簡稱 | ANAL CELL PATHOL | ||||||||||||||||||||||||||||
ISSN | 2210-7177 | ||||||||||||||||||||||||||||
E-ISSN | 2210-7185 | ||||||||||||||||||||||||||||
h-index | 18 | ||||||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||||||
官方網站 | https://www.hindawi.com/journals/acp | ||||||||||||||||||||||||||||
在線稿件提交 | http://mts.hindawi.com/login/ | ||||||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||||||
出版商 | Hindawi Limited | ||||||||||||||||||||||||||||
主題領域 | ONCOLOGY | ||||||||||||||||||||||||||||
出版國/地區 | NETHERLANDS | ||||||||||||||||||||||||||||
發行頻率 | |||||||||||||||||||||||||||||
創刊年 | 2010 | ||||||||||||||||||||||||||||
每年文章數 | 42每年文章數趨勢 | ||||||||||||||||||||||||||||
黃金OA百分比 | 100.00% | ||||||||||||||||||||||||||||
OA Related Info | APC: Yes( USD2000; ) APC waiver:Check Notes Other charges: No Keywords: cytopathology、pathology、cytology Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2210-7177%5BISSN%5D | ||||||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 16 Weeks | ||||||||||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Analytical Cellular Pathology] 的評論 | 撰寫評論 |
作者: Byron Eddie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-13 12:29:36 評論於 Review speed: 12.0 | Submission hit rate: 50.0 Emphasis research direction: bioinformatics; Basic validation experience sharing: This journal is particularly garbage, advising everyone not to submit. I submitted the initial draft in February, received feedback in April, two reviewers were okay, and after answering their comments in early May, it was about to be accepted. However, the journal suddenly said there were problems with the peer review process after acceptance, and the assigned editor was a foreigner I didn't know. Then suddenly re-invited the assigned editor. This process lasted for several months, from May to October, and then re-invited reviewers. The last reviewer was very unfriendly, and although the three questions he raised were not difficult to answer, explain, or modify, he directly rejected the paper without giving a chance for revision, wasting nearly a year. The editor also rejected the paper without even looking at the content. The efficiency of the handling editor was extremely low. The reviewer's comments were replied a month ago, but it took them another month to process. Truly a garbage journal and publishing company. Disappointed with Hindawi, it's only a 3-point level journal. A reviewer made me feel like I submitted to a 10-point journal, most likely a Chinese reviewer(0) 讚! | Byron Eddie |
作者: Byron Eddie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-13 09:36:17 評論於 Do not submit to this magazine, they handle things very slowly, low efficiency of the editors, and no one is willing to review manuscripts. At the same time, Hindawi Publishing Corporation is now on edge, an article that was supposed to be accepted was abruptly rejected. It was only after a mysterious acceptance that problems were found in the peer review process, with the assigned editor being a foreigner and the reviewers unable to see the name. Despite this, they all agreed to accept it, but then another issue arose requiring finding a new editor and resubmission, wasting a lot of time(0) 讚! | Byron Eddie |
作者: 百花高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-20 17:13:56 評論於 Me too, what's happening now?(0) 讚! | 百花高洁 |
作者: 西风佳怡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-02-21 22:04:21 評論於 Do you need the raw data?(0) 讚! | 西风佳怡 |
作者: Alston DeQuincey 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-02-17 18:59:37 評論於 It has been a month, and I have been constantly switching between "submitted" and "AE invited." What's happening?(0) 讚! | Alston DeQuincey |
作者: 风陵山阳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-11-21 13:39:55 評論於 Is it 4.1 now?(0) 讚! | 风陵山阳 |
作者: Horace Watt 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-11 19:47:04 評論於 How are things now?(0) 讚! | Horace Watt |
作者: Horace Watt 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-11 08:41:21 評論於 It has been 2 months and they are still inviting reviewers(0) 讚! | Horace Watt |
作者: Otis Harrington 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-02 10:34:12 評論於 Review speed: 1.0 | Submission hit rate: 75.0 Experience sharing: This journal has a relatively low impact factor, it is in the fourth district of the Chinese Academy of Sciences, and there are not many discussions. Let me give you a timeline: 3.26 submitted; 3.29 Under Review; 4.14 Revision requested; 4.16 Status immediately changed to Under Review after the first revision; 4.22 Reviewers invited; 5.10 Revision requested; 5.18 Status immediately changed to Under Review after the second revision; 7.31 Revision requested; 8.3 Third revision; 8.4 pending approval; 8.5 accepted. I have a question, I don't know if anyone else has encountered it, each of my three revisions only had one reviewer's opinion, I don't know if it's hard to find reviewers. But finally it's over ?(0) 讚! | Otis Harrington |
作者: 一条小嘉蕊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-07-19 10:37:45 評論於 I have been waiting for 20 days and still have not received any feedback from the editor(0) 讚! | 一条小嘉蕊 |
作者: 晶瑶公子 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-30 20:58:59 評論於 Review speed: 2.0 | Submission acceptance rate: 75.0 Experience sharing: A routine bioinformatics article with a simple PCR validation, accepted in a month and a half, very fast(0) 讚! | 晶瑶公子 |
作者: Otis Harrington 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-14 15:12:39 評論於 Hello, how is your article coming along now?(0) 讚! | Otis Harrington |
作者: 天池沛珊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-03-10 11:48:25 評論於 Review Speed: 24.0 | Submission Success Rate: 5.0 Experience Sharing: I submitted a paper in September last year, and it is now in the third round of reviews. The reviewers are still being invited. In the second round, one reviewer agreed to publish and another gave positive feedback with minor revisions. However, it has been a month since the revisions were submitted, and reviewers are still being invited(0) 讚! | 天池沛珊 |
作者: 心慈小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-12-09 10:01:43 評論於 How long is the review process usually?(0) 讚! | 心慈小姐姐 |
作者: 北海振英 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-01-31 21:04:31 評論於 Today is the first day of submission and the status is Under Review. Good luck!(0) 讚! | 北海振英 |
作者: 风啸梦玲 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-11-02 10:28:45 評論於 Does the first trial take 3 months?(0) 讚! | 风啸梦玲 |
作者: 巴蜀红螺 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-11-14 16:26:52 評論於 Review speed: 3.0 | Submission acceptance rate: 25.0 Experience sharing: 1.076(0) 讚! | 巴蜀红螺 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us